Cyclacel Pharmaceuticals, Inc. Stock price
Is Cyclacel Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.
Key metrics
Cyclacel Pharmaceuticals, Inc. Stock Analysis
Analyst Opinions
6 Analysts have issued a Cyclacel Pharmaceuticals, Inc. forecast:
Analyst Opinions
6 Analysts have issued a Cyclacel Pharmaceuticals, Inc. forecast:
Don't miss a Thing! We will send you all news about Cyclacel Pharmaceuticals, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
| Head office | United States |
| CEO | Datuk Wong |
| Employees | 12 |
| Founded | 1996 |
| Website | cyclacel.com |


